CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Liso-Cel Takes Step Toward EU Approval in B-Cell Lymphomas

July 17th 2020

The European Medicines Agency has validated a Marketing Authorization Application for the CD19-directed CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma following at least 2 prior therapies.

CAR T Pioneers Describe Challenges Faced in Cancer

July 16th 2020

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

FDA Issues Clinical Hold on MELANI-01 Trial With UCARTCS1A in Myeloma

July 7th 2020

The FDA has issued a clinical hold on the phase 1 MELANI-01 trial evaluating the CAR T-cell product UCARTCS1A in the treatment of patient with relapsed/refractory multiple myeloma.

Dr. Munshi on Next Steps With Idecabtagene Vicleucel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Ongoing Issues in CAR T-Cell Therapy and Lymphoma

July 2nd 2020

Developing CAR T-Cell Trials

July 2nd 2020

Allogenic CAR T-Cell Therapy in Lymphoma

July 2nd 2020

CAR T-Cell Therapy’s Future for Lymphoma

July 2nd 2020

CAR T Cells and Lymphoma Adverse Events

July 2nd 2020

LBCL Therapy: The Right Therapy

July 2nd 2020

R/R NHL: Candidate Identification and Referrals

July 2nd 2020

CAR T-Cell Therapy for Follicular Lymphoma

July 2nd 2020

ZUMA-2 Trial Overview: Mantle Cell Lymphoma Impact

July 2nd 2020

LDH and ECOG Performance Tests

July 2nd 2020

Liso-cel Therapy in R/R Large B-Cell Lymphoma

July 2nd 2020

The Importance of Antigen Loss in R/R Disease

July 2nd 2020

R/R Large B-Cell Therapy in Managing Various Lymphomas

July 2nd 2020

CAR T-Cell Therapy in Managing Various Lymphomas

July 2nd 2020

Rationale for Further Development of CAR T-Cell therapy

July 2nd 2020

Expert Shares Efforts to Expand Use of CAR T-Cell Therapy to Solid Tumors

June 30th 2020

Natalie Sophia Grover, MD, discusses ongoing research with CAR T-cell therapy in hematologic malignancies, efforts examining the potential for this approach in solid tumors, and future directions and challenges with this modality.